Verve Therapeutics Inc (VERV)

$6.89

+0.07

(+1.03%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $6.69
    $7.06
    $6.89
    downward going graph

    2.98%

    Downside

    Day's Volatility :5.31%

    Upside

    2.41%

    downward going graph
  • $4.59
    $21.04
    $6.89
    downward going graph

    33.38%

    Downside

    52 Weeks Volatility :78.18%

    Upside

    67.25%

    downward going graph

Returns

PeriodVerve Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-0.29%
6.4%
0.0%
6 Months
-44.39%
6.0%
0.0%
1 Year
-65.25%
9.6%
0.0%
3 Years
-86.45%
14.8%
-19.4%

Highlights

Market Capitalization
572.6M
Book Value
$6.96
Earnings Per Share (EPS)
-2.87
Wall Street Target Price
25.88
Profit Margin
0.0%
Operating Margin TTM
-998.14%
Return On Assets TTM
-20.28%
Return On Equity TTM
-36.03%
Revenue TTM
16.0M
Revenue Per Share TTM
0.23
Quarterly Revenue Growth YOY
305.6%
Gross Profit TTM
-128.2M
EBITDA
-215.7M
Diluted Eps TTM
-2.87
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.73
EPS Estimate Next Year
-2.93
EPS Estimate Current Quarter
-0.71
EPS Estimate Next Quarter
-0.73

Analyst Recommendation

Buy
    82%Buy
    17%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Verve Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
13
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 275.62%

Current $6.89
Target $25.88

Technicals Summary

Sell

Neutral

Buy

Verve Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Verve Therapeutics Inc
Verve Therapeutics Inc
34.31%
-44.39%
-65.25%
-86.45%
-85.02%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Verve Therapeutics Inc
Verve Therapeutics Inc
2.34
NA
NA
-2.73
-0.36
-0.2
NA
6.96
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Verve Therapeutics Inc
Verve Therapeutics Inc
Buy
$572.6M
-85.02%
2.34
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Verve Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 7 quarters, 929.0K → 5.69M (in $), with an average increase of 25.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -45.75M → -48.73M (in $), with an average decrease of 3.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 59.9% return, outperforming this stock by 125.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 287.1%

Institutional Holdings

  • Alphabet Inc

    14.71%
  • Vanguard Group Inc

    7.54%
  • ARK Investment Management LLC

    7.19%
  • BlackRock Inc

    6.40%
  • State Street Corporation

    6.07%
  • T. Rowe Price Investment Management,Inc.

    5.45%

Company Information

verve therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. the company brings together human genetics analysis and gene editing – two of the biggest breakthroughs in 21st century biomedicine – to develop transformative therapies for coronary heart disease. verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower ldl cholesterol and triglyceride levels and thereby treat coronary heart disease. founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, verve is backed by a top-tier syndicate of investors, including gv (formerly google ventures), arch venture partners, f-prime capital, biomatics capital, wellington management, casdin capital, and partners innovation fund. the company was recognized as a "2020 best places to work" by the boston business journal. verve is headquartered in cambridge, massachusetts.

Organization
Verve Therapeutics Inc
Employees
255
CEO
Dr. Burt A. Adelman M.D.
Industry
Services

FAQs